Skip to content
Screener

Opus Genetics IRD Q1 2025 Annual earnings

Reported May 15, 2025 · Before market open

Revenue$4.4MBeat by $970.0K
EPS-$0.32Beat by $0.02
Revenue estimate$3.4M
EPS estimate-$0.34

Next report

Nov 11, 2026 (in 2 months)
Revenue estimate$1.5M
EPS estimate-$0.14

Financials

Q1 2025

Income statement

See full
Revenue$4.4M+155%
Operating income-$9.9M-28.8%
Net income-$8.2M-15.3%
EPS (diluted)-$0.24+17.2%

Balance sheet

See full
Cash & equivalents$41.8M-11.4%
Total equity$5.1M-89.0%
Total assets$48.2M-7.1%

Cash flow

See full
Operating cash flow-$9.0M-57.3%

Valuation & ratios

Valuation

as of 03/31/25
See full
Market cap$44.15M—
P/S3.2×—

Profitability

See full
Operating margin-471%-559pp
Net margin-429.4%-512pp

Returns & leverage

See full
Return on equity-229.3%-263pp
Current ratio2×-7.0×

FAQ

When did Opus Genetics report Q1 2025 earnings?
Opus Genetics (IRD) reported Q1 2025 earnings on May 15, 2025 before market open.
What were Opus Genetics's Q1 2025 revenue and EPS?
Opus Genetics reported revenue of $4.4M and eps of $-0.32 for Q1 2025.
Did Opus Genetics beat estimates in Q1 2025?
Revenue beat the consensus estimate of $3.4M by $970.0K. EPS beat the consensus estimate of $-0.34 by $0.02.
How did Opus Genetics's Q1 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 155.4% from $1.7M a year earlier and eps declined 10.3% from $-0.29.
Where can I find Opus Genetics's Q1 2025 SEC filings?
You can read the 8-K earnings release (0001140361-25-019153) and the 10-K periodic report (0001140361-25-011410) directly on SEC EDGAR. The filing index links above go to sec.gov.